Clinical Trial Update: A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating EIK1001 in combination with pembrolizumab and chemotherapy for Stage 4 non-small cell lung cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• EIK1001 (EIK1001)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Eikon Therapeutics | Conditions: NSCLC | Phase 2 | Status: RECRUITING